AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Looking for ways to earn extra cash when busy? Explore practical methods to increase your income without sacrificing your time.
19,658 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
The SNPD ETF is widening its search for dividend growth by applying a 10-year growth screen to identify the next gene...
Retail traders on Robinhood are flocking to a high-yield FANG income ETF, chasing monthly payouts even as upside is c...
Oil remains below $70, but the bigger story is the Federal Reserve's June inflation forecast. This guide explains wha...
Tesla's delivery report just signaled a demand rebound. In this analysis, we uncover three takeaways investors can us...
Three energy-focused ETFs are delivering roughly 7% yields in 2026 while avoiding K-1 tax forms. They promise simpler...
Dave Ramsey renews warnings against raiding retirement savings to pay debt. This report explains the costs and lays o...
A little-known corner of the market, rare earth stocks have moved in big swings. Here's how USA Rare Earth powered an...
Two tech giants define growth storytelling in 2026: one leads cloud security, the other powers AI infrastructure. Thi...
Garmin delivered a dominant Q4 with a big EPS beat and revenue surge, triggering a sharp market rally as investors we...
Tori Spelling says her California rental, home to five children, costs $12,000 a month and feels chaotic. The remark ...
When Apple moves more of its production to the U.S., investors often respond quickly. This article explains why apple...